Fig 2. Disease-free and overall survival in (A, B) responding, (C, D) nonresponding, and (E, F) all patients comparing response-guided with conventional.

Slides:



Advertisements
Similar presentations
Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple.
Advertisements

OPEN ISSUES IN MULTIDISCIPLINARY BREAST CANCER MANAGEMENT
The phase III ICE study: Adjudiscloseant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer Gunter.
Taxanes — Taxanes are among the most active agents for metastatic breast cancer – Docetaxel, Paclitaxel, NabPaclitaxel. Anthracyclines – Doxorubicin, Epirubicin,
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann Journal.
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Volume 34, Pages (August 2017) Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the.
A. Schema of NSABP B-27 trial comparing neoadjuvant AC to neoadjuvant AC followed by neoadjuvant docetaxel and to neoadjuvant AC followed by adjuvant docetaxel.
Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)  M. Yoshida, K. Muro, A. Tsuji,
The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study  Ying Li, Sheng Zhang, Xi.
The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis  K.
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced.
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing  Klazien Matter-Walstra, PhD, Matthias.
Anxiety After Diagnosis Predicts Lung Cancer–Specific and Overall Survival in Patients With Stage III Non–Small Cell Lung Cancer: A Population-Based Cohort.
Khaled M. Madbouly, Abdrabou N. Mashhour, Waleed Omar 
Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up  Marco Lucchi, MD, Franca Melfi, MD, Paolo.
European Urology Oncology
Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka 
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Volume 64, Issue 3, Pages (September 2013)
Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis 
Pain in cancer survivors; filling in the gaps
Volume 53, Issue 6, Pages (June 2008)
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients 
Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin.
Volume 143, Issue 4, Pages (October 2012)
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians)  Carsten Nieder, Thomas A.
Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients  Jean-Louis Pujol, MD, Patrick.
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Pulmonary Resection for Metastatic Gastric Cancer
Long-term results of simultaneous carotid endarterectomy and myocardial revascularization with cardiopulmonary bypass used for both procedures  Kazutomo.
Volume 152, Issue 1, Pages (January 2019)
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.
Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations  Benjamin Haaland, PhD, Pui San Tan,
Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging  Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,
Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database  Laura C. Caprario, MD, MS,
Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small.
Axillary-axillary interarterial chest loop conduit as an alternative for chronic hemodialysis access  Carsten Michael Bünger, MD, Jens Kröger, MD, Lars.
Randomized Phase III Trial of Docetaxel Plus Carboplatin with or without Levofloxacin Prophylaxis in Elderly Patients with Advanced Non-small Cell Lung.
Integrated Onco-Palliative Care Associated With Prolonged Survival Compared to Standard Care for Patients With Advanced Lung Cancer: A Retrospective Review 
International Journal of Cardiology
Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients 
Laparoscopic treatment of renal artery entrapment
Antidepressant use and risk for mortality in 121,252 heart failure patients with or without a diagnosis of clinical depression  Corline Brouwers, Stefan.
The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer  Thomas E. Stinchcombe, MD, Harry.
Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced.
J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin 
Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors 
Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J
Community-acquired acute bacterial meningitis in the elderly in Turkey
Supportive care for patients with renal disease: Time for action
Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma Registry  Ulrike.
Gastroenterology  Volume 124, Issue 4, (April 2003) DOI: /S (03)
The future of cardiac surgery training: A survival guide
European Urology Oncology
APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28
Fig 1. CONSORT diagram. (*) One patient who was randomly assinged to placebo actually received abemaciclib during cycle one. This patient is counted in.
Jamie E. Chaft, MD, Camelia S. Sima, MD, MS, Michelle S
Induction Therapy For Locally Advanced Thymoma
A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.
Time to progression and overall survival for patients according to four factors (in order, top to bottom): debulking surgery or not, residual disease after.
Presentation transcript:

Fig 2. Disease-free and overall survival in (A, B) responding, (C, D) nonresponding, and (E, F) all patients comparing response-guided with conventional chemotherapy. NX, vinorelbine and capecitabine; TAC, docetaxel, doxorubicin, and cyclophosphamide. Published in: Gunter von Minckwitz; Jens Uwe Blohmer; Serban Dan Costa; Carsten Denkert; Holger Eidtmann; Wolfgang Eiermann; Bernd Gerber; Claus Hanusch; Jörn Hilfrich; Jens Huober; Christian Jackisch; Manfred Kaufmann; Sherko Kümmel; Stefan Paepke; Andreas Schneeweiss; Michael Untch; Dirk Michael Zahm; Keyur Mehta; Sibylle Loibl; Journal of Clinical Oncology 2013 313623-3630. DOI: 10.1200/JCO.2012.45.0940 Copyright © 2013

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.